Neumora Therapeutics, Stock Analysis
| NMRA Stock | 1.20 0.07 6.19% |
Neumora Therapeutics, is overvalued with Real Value of 1.15 and Target Price of 15.54. The main objective of Neumora Therapeutics, stock analysis is to determine its intrinsic value, which is an estimate of what Neumora Therapeutics, is worth, separate from its market price. There are two main types of Neumora Therapeutics,'s stock analysis: fundamental analysis and technical analysis.
The Neumora Therapeutics, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Neumora Therapeutics,'s ongoing operational relationships across important fundamental and technical indicators.
Neumora |
Neumora Stock Analysis Notes
About 28.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neumora Therapeutics, recorded a loss per share of 1.53. The entity had not issued any dividends in recent years. To find out more about Neumora Therapeutics, contact Henry Gosebruch at 857 760 0900 or learn more at https://www.neumoratx.com.Neumora Therapeutics, Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Neumora Therapeutics,'s investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Neumora Therapeutics, or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Neumora Therapeutics, generated a negative expected return over the last 90 days | |
| Neumora Therapeutics, has high historical volatility and very poor performance | |
| Neumora Therapeutics, may become a speculative penny stock | |
| Net Loss for the year was (243.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neumora Therapeutics, generates negative cash flow from operations | |
| About 72.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Neumora Therapeutics, Inc. Investors April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer Check, LLP |
Neumora Therapeutics, Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neumora Therapeutics, previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Neumora Largest EPS Surprises
Earnings surprises can significantly impact Neumora Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.3803 | -0.45 | -0.0697 | 18 | ||
2025-03-03 | 2024-12-31 | -0.4423 | -0.37 | 0.0723 | 16 | ||
2024-03-07 | 2023-12-31 | -0.55 | -0.71 | -0.16 | 29 |
Neumora Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 194.37 M.Neumora Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (0.92) | (0.96) | |
| Return On Assets | (0.77) | (0.81) | |
| Return On Equity | (0.85) | (0.81) |
Management Efficiency
Neumora Therapeutics, has return on total asset (ROA) of (0.405) % which means that it has lost $0.405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6448) %, meaning that it created substantial loss on money invested by shareholders. Neumora Therapeutics,'s management efficiency ratios could be used to measure how well Neumora Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of March 25, 2025, Return On Tangible Assets is expected to decline to -0.81. In addition to that, Return On Capital Employed is expected to decline to -0.96. At present, Neumora Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 328.1 M, whereas Net Tangible Assets are projected to grow to (382.1 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.80 | 1.89 | |
| Tangible Book Value Per Share | 1.80 | 1.89 | |
| Enterprise Value Over EBITDA | (5.88) | (6.17) | |
| Price Book Value Ratio | 5.89 | 6.18 | |
| Enterprise Value Multiple | (5.88) | (6.17) | |
| Price Fair Value | 5.89 | 6.18 |
The strategic initiatives led by Neumora Therapeutics,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 25th of March, Neumora Therapeutics, secures the Risk Adjusted Performance of (0.15), mean deviation of 5.13, and Standard Deviation of 11.07. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neumora Therapeutics,, as well as the relationship between them.Neumora Therapeutics, Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Neumora Therapeutics, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Neumora Therapeutics,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Neumora Therapeutics, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neumora Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neumora Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neumora Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neumora Therapeutics, Outstanding Bonds
Neumora Therapeutics, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neumora Therapeutics, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neumora bonds can be classified according to their maturity, which is the date when Neumora Therapeutics, has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Neumora Therapeutics, Predictive Daily Indicators
Neumora Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neumora Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Neumora Therapeutics, Forecast Models
Neumora Therapeutics,'s time-series forecasting models are one of many Neumora Therapeutics,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neumora Therapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Neumora Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Neumora Therapeutics, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neumora shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Neumora Therapeutics,. By using and applying Neumora Stock analysis, traders can create a robust methodology for identifying Neumora entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Neumora Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neumora analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neumora analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 15.54 | Strong Buy | 9 | Odds |
Most Neumora analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neumora stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neumora Therapeutics,, talking to its executives and customers, or listening to Neumora conference calls.
Neumora Stock Analysis Indicators
Neumora Therapeutics, stock analysis indicators help investors evaluate how Neumora Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neumora Therapeutics, shares will generate the highest return on investment. By understating and applying Neumora Therapeutics, stock analysis, traders can identify Neumora Therapeutics, position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 375.3 M | |
| Common Stock Shares Outstanding | 159.4 M | |
| Total Stockholder Equity | 287.1 M | |
| Tax Provision | 178 K | |
| Property Plant And Equipment Net | 2.9 M | |
| Cash And Short Term Investments | 307.6 M | |
| Cash | 142.1 M | |
| Accounts Payable | 3.3 M | |
| Net Debt | -140.3 M | |
| 50 Day M A | 1.7161 | |
| Total Current Liabilities | 29.9 M | |
| Non Current Assets Total | 2.9 M | |
| Stock Based Compensation | 40 M |
Complementary Tools for Neumora Stock analysis
When running Neumora Therapeutics,'s price analysis, check to measure Neumora Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neumora Therapeutics, is operating at the current time. Most of Neumora Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Neumora Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neumora Therapeutics,'s price. Additionally, you may evaluate how the addition of Neumora Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |